1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24356
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKalbakis, K.en
dc.contributor.authorPappas, P.en
dc.contributor.authorKouroussis, C.en
dc.contributor.authorVamvakas, L.en
dc.contributor.authorKalykaki, A.en
dc.contributor.authorVardakis, N.en
dc.contributor.authorNikolaidou, M.en
dc.contributor.authorMarselos, M.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorMavroudis, D.en
dc.date.accessioned2015-11-24T19:40:27Z-
dc.date.available2015-11-24T19:40:27Z-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24356-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subject*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/pharmacokinetics/therapeutic useen
dc.subjectDisease-Free Survivalen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDoxorubicin/administration & dosage/adverse effects/pharmacokinetics/therapeuticen
dc.subjectuseen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Invasivenessen
dc.subjectNeoplasms/*drug therapy/pathologyen
dc.subjectOrganoplatinum Compounds/administration & dosage/adverseen
dc.subjecteffects/pharmacokinetics/therapeutic useen
dc.subjectPaclitaxel/administration & dosage/adverse effects/pharmacokinetics/therapeuticen
dc.subjectuseen
dc.titleA dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumorsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00280-007-0624-3-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17960381-
heal.identifier.secondaryhttp://www.springerlink.com/content/7447319178378k8w/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2008-
heal.abstractPURPOSE: To evaluate the maximum tolerated doses (MTD) and the dose-limiting toxicities (DLT) of the combination of pegylated liposomal doxorubicin (PEG-LD), paclitaxel and oxaliplatin (L-OHP) administered every 2 weeks in patients with advanced solid tumors. METHODS: Thirty-nine pretreated patients with advanced solid tumors received escalated doses of PEG-LD (10-16 mg/m(2)), paclitaxel (100-120 mg/m(2)) and L-OHP (50-70 mg/m(2)) every 2 weeks. As one cycle of treatment was considered the administration of both drugs on days 1 and 15 of a 4-week cycle. RESULTS: The MTDs were PEG-LD 14 mg/m(2), paclitaxel 120 mg/m(2) and L-OHP 70 mg/m(2). Neutropenia was the DLT in all but one case with only one episode of febrile neutropenia and no toxic deaths. Four (4%) and 13 (12%) cycles were complicated by grades 4 and 3 neutropenia, respectively. Grades 2-3 fatigue and neurotoxicity occurred in 13 and 12% of cycles, respectively. Responses were observed in patients with breast, endometrial and ovarian carcinomas. CONCLUSIONS: This is a quite well-tolerated regimen which merits further evaluation in phase II studies.en
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Kalbakis-2008-A dose escalation an.pdf390.85 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons